Whether you are building a competitive landscape of PD-1 inhibitors in NSCLC, identifying mid-cap biotechs with late-stage oncology pipelines, or screening Phase 3 trials by enrollment criteria, Maven Bio's built-in filters let you scope precise entity lists without writing queries. Combine filters across scientific, regulatory, clinical, financial, and company dimensions to build exactly the list your analysis requires.

Filters follow AND/OR logic: items must satisfy all applied conditions. A few approaches that work well in practice:

Scope drug lists by development context, modality, mechanism, clinical characteristics, and sponsoring company. Start with development status (global status, US status, active/inactive) and layer on product type (small molecule, antibody, gene therapy, cell therapy, radiopharmaceutical, vaccine), regulatory designations (Orphan Drug, Fast Track, Breakthrough Therapy, PRIME, RMAT, QIDP), and clinical attributes (patient population, route of administration, adverse events). Mechanistic filters (MOA, targets, drug classes) and indication filters anchor results in scientific space. Company filters, including primary-company market cap, add a business lens for BD or investment analysis.

Scope trial lists by study design, geography, population, interventions, and sponsor. Filter by NCT ID, study type, trial status, start and completion dates, therapeutic area, and trial focus. Refine further with enrollment criteria, gender eligibility, healthy volunteer acceptance, inclusion/exclusion criteria, and outcomes measured. Study design characteristics (allocation, intervention model, masking, objectives) let you isolate specific trial designs.

Scope company lists by identity (name, HQ country, stock exchange, ticker, employee count), pipeline depth (total active programs, mechanisms, targets, indications, highest phase reached), and financials (market cap, revenue, net income, EBITDA, free cash flow). These filters support pipeline-based company screening and financial segmentation for BD, strategy, or investment workflows.

Each entity type supports filtering by name, associated drugs and companies, linked therapeutic areas, highest development phase, total and active program counts, and active-program percentage. These are useful for target-based competitive analysis and indication-level landscape building.

Scope document lists by title, document type (press releases, earnings transcripts, SEC filings, publications, corporate presentations), publication date, source URL, and associated companies or drugs. Conference abstracts add filters for abstract phase, presentation type, conference name and year, primary author, author institution, and key findings.

After scoping your list, save the search so you can reapply it later, or add AI Columns to enrich the filtered results with custom analysis.